Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation
Executive Summary
The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.
You may also be interested in...
Gilead Adds To Virology Focus Through 12-Year Collaboration With Assembly
Gilead gets option rights to Assembly’s entire virology pipeline, including future assets, for herpesvirus and hepatitis B and D. The deal provides financial stability and opt-in potential for Assembly.
Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
Antios Says Its Novel Hepatitis B Mechanism Can Help Toward Functional Cure
First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.